https://pioneerinstitute.org/wp-content/uploads/MBTA-Subway-Returns-Feature.jpg 450 600 Eamon McCarthy Earls https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Eamon McCarthy Earls2019-04-01 16:48:532019-07-11 11:23:44MBTAAnalysis: A look inside the MBTA
The MBTA shuttles over a million passengers a day around Greater…
https://pioneerinstitute.org/wp-content/uploads/CloseupClock-1.jpg 739 1244 Mary Connaughton https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Mary Connaughton2017-02-20 12:34:192017-02-21 09:47:58The Clock is Ticking…….
The clock is ticking towards December 30, 2017. As part of…
https://pioneerinstitute.org/wp-content/uploads/The-QALY-and-Cancer-Treatments_-An-Ill-Advised-Match.png 512 1024 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2021-04-06 04:45:242021-04-06 11:22:33New Analysis: ICER Framework Ignores Patient Preferences, Innovation & Societal Benefits in Evaluating Cost-Effectiveness of New Cancer Treatments
Pioneer Institute today released a new analysis, The QALY and Cancer Treatments: An Ill-Advised Match, that examines the alarming methodological and contextual shortcomings of the Quality Adjusted Life Years (QALY)-based methodology in evaluating new cancer therapies. The Pioneer Institute analysis reveals five specific problems with ICER’s evaluation of cancer treatments and demonstrates the urgent need to prohibit the use of the QALY amid trends in rapid cancer innovations and personalized medicine.